Synergistic activities of a silver(I) glutamic acid complex and reactive oxygen species (ROS): A novel antimicrobial and chemotherapeutic agent

Current Medicinal Chemistry

Volumn 19, Issue 21, 2012, Pages 3635-3640

  Batarseh, K I ^a,b   Smith, M A ^c  

^a NovaGene LLC   (United States)

^b Alpha Omega Biologicals   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial; Chemotherapy; Escherichia coli; Glutamic acid; MCF 7; Reactive oxygen species (ROS); Silver; Staphylococcus aureus; Vero

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; GENTAMICIN; GLUTAMIC ACID; HYDROGEN PEROXIDE; HYDROXYL RADICAL; OXACILLIN; PENICILLIN G; REACTIVE OXYGEN METABOLITE; SILVER; SILVER GLUTAMIC ACID COMPLEX; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SYNTHESIS; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; TUMOR CELL;

EID: 84863740165     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801323216     Document Type: Article

References (38)

1. Spencer, R. C. Bacillus anthracis. J. Clinical Path., 2003, 56, 182-187.
2. Serizawa, M.; Sekizuka, T.; Okutani, A.; Banno, S.; Sata, T.; Inoue, S.; Kuroda, M. Genome-wide screening for novel genetic variations associated with ciprofloxacin resistance in Bacillus anthracis. Antimicrob. Agents Chemother., 2010, 54, 2787-2792.
3. Vergison, A., Dagan, R.; Arguedas, A.; Bonhoeffer, J.; Cohn, R.; Hooge, I.D.; Hoberman, A.; Liese, J.; Marchisio, P.; Palmu, A.; Ray, G.; Sanders, E.; Simões, E.; Uhari, M.; van Eldere, J.; Pelton, S. Otitis media and its consequences: beyond the earache. The Lancet Infect. Dis, 2010, 10, 195-203.
4. Garau, J. Treatment of drug-resistance Pneumococcal pneumonia. The Lancet Infect. Dis., 2002, 2, 404-415.
5. Fisher, K.; Phillips, C. The ecology, epidemiology and virulence of Enterococcus. Microbiol., 2009, 155, 1749-1757.
6. Lowy, F.D. Staphylococcus aureus infections. New Engl. J. Med., 1998, 339, 520-532.
7. Jemal, A.; Siegel, R.R.; Ward, E.; Hao, Y.; Xu, J.; Murria, T.; Thun, M.J. Cancer statistics. CA Cancer J. Clin., 2008, 58, 71-96.
8. Jakupec, M.; Galanski, M.; Keppler, B. Tumor-inhibiting platinum complexes-state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol., 2003, 146, 1-53.
9. Muggia, F. Platinum Coordination Compounds in Cancer Chemotherapy. Elsevier: Philadelphia, 2005.
10. Muggia, F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gyn. Oncol. 2009, 112, 275-317.
11. Moayeri, M.; Wiggins, J.F.; Lindeman, R.E.; Leppla, S.H. Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother., 2006, 50, 2658-2665.
12. de Thé, H.; Chen, Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010, 10, 775-783.
13. Jain, R.K. Vascular and interstitial biology of tumors. In: Clinical Oncology; Abeloff, M.; Armitage, J.; Kastan, M.; McKenna, G.; Niederhuber, J.; Meloni, D., Eds; 3rd Edition. Elsevier: Philadelphia, 2008; pp. 105-124.
14. Loui, C.; Chang, A.C.; Lu, S. Role of the ArcAB two-component system in the resistance of Escherichia coli to reactive oxygen stress. BMC Microbiology, 2009, 9, 183.
15. Fridovich, I. The biology of oxygen radicals. Science 1978, 201, 875-880.
16. Haber, F.; Weiss, J. Über die Katalyse des Hydroperoxydes. Naturwissenschaften, 1932, 20, 948-950.
17. Fenton, H.J.H. Oxidation of tartaric acid in the presence of iron. J. Chem. Soc., 1894, 65, 899-910.
18. Batarseh, K.I. Anomaly and correlation of killing in the therapeutic properties of silver (I) chelation with glutamic and tartaric acids. J. Antimicrob. Chemo., 2004, 54, 546-548.
19. Batarseh, K.I. Apoptosis-inducing antineoplastic silver (I) coordination complexes. European Patent Application No. 1845997, 2007.
20. Batarseh, K.I. Apoptosis-inducing antineoplastic silver (I) coordination complexes. International Patent Application No. PCT/US 2006/000390, 2007.
21. Batarseh, K.I. A novel silver (I) chelate: cytotoxicity and apoptotic mechanism of action on human hematopoietic malignancies. Leukemia, 2008, 22, 448-450.
22. Batarseh, K.I. In: Advances in Cancer Research: From the Laboratory to the Clinic, Presented at the Proceedings of the American Association for Cancer Research (AACR) International Conference, Dead Sea, Jordan, March 16-19, 2008.
23. Batarseh, K.I. Antimicrobial, in vitro and in vivo antineoplastic activities, mechanism of action, and structural and thermal properties of a small-novel pharmaceutical organometallic chelate. Mini Rev. Med. Chem., 2009, 9, 293-299.
24. Batarseh, K.I. Apoptosis-inducing antineoplastic silver (I) coordination complexes. U.S. Patent 8,048,870, November 1, 2011.
25. Batarseh, K.I. Chemotherapeutic and prophylactic pharmaceutical compositions. U.S. Patent Application No. US 2005/0276795 A1, 2007.
26. Wisplinghoff, H.; Bischoff, T.; Tallent, S.M.; Seifert, H.; Wenzel, R.P; Edmond; M.B. Nosocomial blood stream infections in US Hospitals; analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis., 2004, 39, 309-317.
27. Kaplan, N.O. In: The Enzymes; Boyer, P.D.; Lardy, H.; Myrblick, K., Eds.; Academic Press: New York, 1960; Vol. 3, pp. 159.
28. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th 280 ed. Approved Standard. NCCLS publication no. M7-A6. National Committee for Clinical Laboratory Standards. Wayne: PA, 2003.
29. Hurst, J.K.; Barerette, W.C. Leukocyte oxygen activation and microbicidal oxidative toxin.CRC Biochem. Mol. Biol., 1989, 24, 217-328.
30. Low, D.E.; Kreiswirth, B.N.; Weiss, K.; Willey, B.M. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int. J. Antimicrob. Agents, 2002, 20, 220-222.
31. S. aureus ATCC 29213(syn NCTC 12973). http://www.srga.org/Refstam/ sa29213.htm (Accessed February 4, 2012).
32. Kerbel, R.S.; Kamen, B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer, 2004, 4, 423-436.
33. Pietras, K.; Hanahan, D.A. Multitargeted, metronomic, and maximumtolerated dose "Chemo-Switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol., 2005, 23, 939-952.
34. Alwi, S.; Nallappan, M.; Pihie; A. Zerumbone exerts antiproliferative activity via apoptosis on HepG2 cells. Malay. J. Biochem. Mol. Biol., 2007, 15, 19-23.
35. Yoshimaru, T.; Suzuki, Y.; Inoue, T.; Niide, O.; Ra, C. Silver activates mast cells through reactive oxygen species production and a thiol-sensitive storeindependent Ca+2 influx. Free Radic. Biol. Med., 2006, 40, 1949-1959.
36. Cortese-Krott, M.M.; Münchow, M.; Pirev, E.; Hener, F.; Bozkurt, A.; Uciechowski, P.; Pallua, N.; Kröncke, K.D.; Suschek, C.V. Silver ions induce oxidative stress and intracellular zinc release in human skin fibroblasts. Free Radic. Biol.Med., 2009, 47, 1570-1577.
37. ATSDR. Toxicological profile for silver. http://www.atsdr.cdc.gov/ toxprofiles/tp146-p.pdf (Accessed February 4, 2012).
38. IRIS. Silver. http://www.epa.gov/iris/subst/0099.htm (Accessed February 4, 2012).